CALA

Calithera Biosciences, Inc. is a clinical-stage, precision oncology biopharmaceutical company. The Company is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The Company is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The Company is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The Company's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.